Among the clinical features investigated by the authors, it was interesting to notice that when analysing the clinical response to radiation and temozolomide combination treatment, it appeared that tumours from the astrocytic subclass have a significant survival benefit, even though the most significant association between MGMT promoter methylation and longer survival was observed in the neuro‐mesenchymal subclass. This evidence concerns the gene MGMT and neoplasm.